The MSG held its annual meeting on September 19-21, 2011, at Beaver Hollow Conference Center, Java Center, NY. The meeting was entitled “Translational Research in Neuromuscular Diseases: Diverse Diseases, Convergent Themes.” The meeting brought together members of the pharmaceutical industry and academic researchers.
The agenda included five major sessions: RNA Metabolism as Therapeutic Target in Muscle Disease, RNA Metabolism as Therapeutic Target in Motor Neuron Disease, Government/Foundation Perspectives on NM Themes, Animal Models and Translational Research, and Exercise as a Therapy for NM Disease.
The Muscle Study Group received permission to post the following abstracts online.
Fat Metabolism Syndrome in Patients with DMD Following Low Energy Femur Fracture – Emma Ciafaloni
Plasma Exchange Complications are Related to the Venous Access Route – Jeffrey Guptill
A Prospective, Randomized Controlled Trial of Valproic Acid in Ambulant Adults with SMA: The VALIANT Trial – John Kissel
Amyloidosis and Exercise Tolerance in AN05 Muscular Dystrophy – Margherita Milone
MRI Quantification of Lower Limb Muscle Fatty Atrophy: A Potential Outcome Measure in Chronic NM Diseases – Jasper Morrow
Identifying the Cause of Phenotypic Variability in a Family with NDM – Dips Raja Rayan
The meeting was sponsored by:
- National Institutes of Health, Grant #1R13NS076196-01
- Muscular Dystrophy Association
- ISIS Pharmaceuticals
- PTC Therapeutics
- Crescent Healthcare, Inc.
- Genzyme Corporation